Current and future trends in the anatomical and functional imaging of head and neck paragangliomas

Seminars in Nuclear Medicine

Volumn 43, Issue 6, 2013, Pages 462-473

  Taïeb, David ^a   Varoquaux, Arthur ^a   Chen, Clara C ^b   Pacak, Karel ^c  

^a TIMONE HOSPITAL   (France)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPA F 18; CARBIDOPA; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR;

ALGORITHM; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; HEAD AND NECK TUMOR; HUMAN; IMAGING; METASTASIS; PARAGANGLIOMA; PATIENT SELECTION; PHYSICAL EXAMINATION; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; RADIOLOGIST; RADIOTHERAPY; SCINTISCANNING; TREATMENT PLANNING;

ALGORITHMS; DIAGNOSTIC IMAGING; HEAD AND NECK NEOPLASMS; HUMANS; PARAGANGLIOMA;

EID: 84885117944     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2013.06.005     Document Type: Article

References (69)

1. J.M. Sykes, and R.H. Ossoff Paragangliomas of the head and neck Otolaryngol Clin North Am 19 1986 755 767
2. M. Jafri, J. Whitworth, and E. Rattenberry Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma Clin Endocrinol (Oxf) 78 2013 898 906
3. V. Piccini, E. Rapizzi, and A. Bacca Head and neck paragangliomas: Genetic spectrum and clinical variability in 79 consecutive patients Endocr Relat Cancer 19 2012 149 155
4. H.X. Hao, O. Khalimonchuk, and M. Schraders SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma Science 325 2009 1139 1142
5. H.P. Neumann, M. Sullivan, and A. Winter Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites J Clin Endocrinol Metab 96 2011 E1279 E1282
6. J. Gaal, F.H. van Nederveen, and Z. Erlic Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome J Clin Endocrinol Metab 94 2009 4367 4371
7. B.E. Baysal Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors Biochim Biophys Acta 1827 2013 573 577
8. H.P. Neumann, Z. Erlic, and C.C. Boedeker Clinical predictors for germline mutations in head and neck paraganglioma patients: Cost reduction strategy in genetic diagnostic process as fall-out Cancer Res 69 2009 3650 3656
9. C. Ricketts, E.R. Woodward, and P. Killick Germline SDHB mutations and familial renal cell carcinoma J Natl Cancer Inst 100 2008 1260 1262
10. B. Pasini, S.R. McWhinney, and T. Bei Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD Eur J Hum Genet 16 2008 79 88
11. P. Xekouki, K. Pacak, and M. Almeida Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: A new association for SDH? J Clin Endocrinol Metab 97 2012 E357 E366
12. G. Eisenhofer, J.W. Lenders, and G. Siegert Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status Eur J Cancer 48 2012 1739 1749
13. B.E. Baysal, J.E. Willett-Brozick, and E.C. Lawrence Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas J Med Genet 39 2002 178 183
14. H.P. Kunst, M.H. Rutten, and J.P. de Monnink SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma Clin Cancer Res 17 2011 247 254
15. H.J. Timmers, A.P. Gimenez-Roqueplo, and M. Mannelli Clinical aspects of SDHx-related pheochromocytoma and paraganglioma Endocr Relat Cancer 16 2009 391 400
16. M.H. Johnson Head and neck vascular anatomy Neuroimaging Clin N Am 8 1998 119 141
17. R. van den Berg, A. Schepers, and F.T. de Bruine The value of MR angiography techniques in the detection of head and neck paragangliomas Eur J Radiol 52 2004 240 245
18. F. Neves, L. Huwart, and G. Jourdan Head and neck paragangliomas: Value of contrast-enhanced 3D MR angiography AJNR Am J Neuroradiol 29 2008 883 889
19. R. van den Berg Imaging and management of head and neck paragangliomas Eur Radiol 15 2005 1310 1318
20. S.M. Arnold, R. Strecker, and K. Scheffler Dynamic contrast enhancement of paragangliomas of the head and neck: Evaluation with time-resolved 2D MR projection angiography Eur Radiol 13 2003 1608 1611
21. T.M. Grist, C.A. Mistretta, and C.M. Strother Time-resolved angiography: Past, present, and future J Magn Reson Imaging 36 2012 1273 1286
22. Y. Dong, and Q. Liu Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T J Comput Assist Tomogr 36 2012 361 366
23. 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease Endocr Relat Cancer 19 2012 83 93
24. 111In-pentetreotide scintigraphy J Clin Endocrinol Metab 96 2011 2779 2785
25. A. Bustillo, F. Telischi, and D. Weed Octreotide scintigraphy in the head and neck Laryngoscope 114 2004 434 440
26. M. Duet, E. Sauvaget, and B. Petelle Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck J Nucl Med 44 2003 1767 1774
27. 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas J Nucl Med 49 2008 1232 1237
28. 111In- pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma Nucl Med Commun 19 1998 735 742
29. M. Schmidt, E. Fischer, and M. Dietlein Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas Eur J Nucl Med Mol Imaging 29 2002 1571 1580
30. F.F. Telischi, A. Bustillo, and M.L. Whiteman Octreotide scintigraphy for the detection of paragangliomas Otolaryngol Head Neck Surg 122 2000 358 362
31. A.P. Gimenez-Roqueplo, A. Caumont-Prim, and C. Houzard Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: A multicenter prospective study from the PGL.EVA investigators J Clin Endocrinol Metab 98 2013 E162 E173
32. 123I-MIBG in identifying malignant neural crest tumours Mol Imaging Biol 13 2011 769 775
33. 68Ga-labelled peptides in the management of neuroectodermal tumours Eur J Nucl Med Mol Imaging 39 suppl 1 2012 61 67
34. 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma Eur J Nucl Med Mol Imaging 39 2012 1266 1270
35. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med 2013;54:841-847
36. 68Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur J Nucl Med Mol Imaging 32 2005 724
37. D. Wild, J.S. Schmitt, and M. Ginj DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur J Nucl Med Mol Imaging 30 2003 1338 1347
38. J.C. Reubi, J.C. Schar, and B. Waser Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 2000 273 282
39. 11C-hydroxyephedrine positron emission tomography imaging of pheochromocytoma: A single center experience over 11 years J Clin Endocrinol Metab 97 2012 2423 2432
40. B.L. Shulkin, N.W. Thompson, and B. Shapiro Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET Radiology 212 1999 35 41
41. H.J. Timmers, A. Kozupa, and C.C. Chen Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma J Clin Oncol 25 2007 2262 2269
42. 18F-FDG avidity of pheochromocytomas and paragangliomas: A new molecular imaging signature? J Nucl Med 50 2009 711 717
43. 18F-FDG) positron emission tomography J Natl Cancer Inst 104 2012 700 708
44. 18F DOPA whole body PET - initial results Radiology 222 2002 507 512
45. 18F-DOPA positron emission tomography for the detection of glomus tumours Eur J Nucl Med Mol Imaging 30 2003 689 694
46. 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma J Clin Endocrinol Metab 94 2009 4757 4767
47. 1F]FDOPA-PET in the localization of extra-adrenal paragangliomas: The case for a patient-tailored use of nuclear imaging modalities Clin Endocrinol (Oxf) 74 2011 21 29
48. Gabriel S, Blanchet EM, Sebag F, et al. Functional characterization of non-metastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: Focus on missed lesions. Clin Endocrinol (Oxf), in press. doi:10.1111/cen.12126
49. Miederer M, Fottner C, Rossmann H, et al. High incidence of extraadrenal paraganglioma in families with SDHx syndromes detected by functional imaging with [(18)F]fluorodihydroxyphenylalanine PET. Eur J Nucl Med Mol Imaging 2013;40:889-896
50. H.C. Rischke, M.R. Benz, and D. Wild Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET J Nucl Med 53 2012 1352 1358
51. D. Taieb, H. Neumann, and D. Rubello Modern nuclear imaging for paragangliomas: Beyond SPECT J Nucl Med 53 2012 264 274
52. H.J. Timmers, D. Taieb, and K. Pacak Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma Horm Metab Res 44 2012 367 372
53. G. Treglia, F. Cocciolillo, and C. de Waure Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: A meta-analysis Eur J Nucl Med Mol Imaging 39 2012 1144 1153
54. M. Hentschel, C. Rottenburger, and C.C. Boedeker Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas? Clin Nucl Med 37 2012 e24 e29
55. H.J. Timmers, M. Hadi, and J.A. Carrasquillo The effects of carbidopa on uptake of 6-18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma J Nucl Med 48 2007 1599 1606
56. U. Fisch, and D. Mattox Microsurgery of the Skull Base 1988 Georg Thieme Verlag 1998 Stuttgart/New York 148 281
57. U. Fisch Infratemporal fossa approach to tumours of the temporal bone and base of the skull J Laryngol Otol 92 1978 949 967
58. J.L. Netterville, C.G. Jackson, and F.R. Miller Vagal paraganglioma: A review of 46 patients treated during a 20-year period Arch Otolaryngol Head Neck Surg 124 1998 1133 1140
59. W.R. Shamblin, W.H. ReMine, and S.G. Sheps Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases Am J Surg 122 1971 732 739
60. J.L. Netterville, K.M. Reilly, and D. Robertson Carotid body tumors: A review of 30 patients with 46 tumors Laryngoscope 105 1995 115 126
61. L.C. Bianchi, M. Marchetti, and L. Brait Paragangliomas of head and neck: A treatment option with CyberKnife radiosurgery Neurol Sci 30 2009 479 485
62. P.G. Chen, J.H. Nguyen, and S.C. Payne Treatment of glomus jugulare tumors with gamma knife radiosurgery Laryngoscope 120 2010 1856 1862
63. A. Navarro Martin, A. Maitz, and I.S. Grills Successful treatment of glomus jugulare tumours with gamma knife radiosurgery: Clinical and physical aspects of management and review of the literature Clin Transl Oncol 12 2010 55 62
64. Z.D. Guss, S. Batra, and C.J. Limb Radiosurgery of glomus jugulare tumors: A meta-analysis Int J Radiat Oncol Biol Phys 81 2011 e497 e502
65. A. Cascon, and D.A. Tennant From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma Endocr Pathol 23 2012 15 20
66. U. Shankavaram, S.M. Fliedner, and A.G. Elkahloun Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas Neoplasia 15 2013 435 447
67. J. Favier, P.F. Plouin, and P. Corvol Angiogenesis and vascular architecture in pheochromocytomas: Distinctive traits in malignant tumors Am J Pathol 161 2002 1235 1246
68. Rogers JL, Bayeh L, Scheuermann TH, et al. Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor. J Med Chem, in press. doi:10.1021/jm301847z
69. S.T. Lo, A. Kumar, and J.T. Hsieh Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry Mol Pharm 10 2013 793 812